MNKD

MannKind Corporation

5.11 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MannKind Corporation stock is up 6.02% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55% of the previous 19 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 May 15:54 17 May, 2024 3.00 CALL 200 2225
20 Jun 18:23 17 Jan, 2025 5.50 CALL 2497 1626

About MannKind Corporation

MannKind focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.